Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status

被引：129
|
作者：
Ikeda, Y [1 ]
Umemura, K
Kondo, K
Sekiguchi, K
Nakashima, M
机构：
[1] Hamamatsu Univ Sch Med, Hamamatsu, Shizuoka 43131, Japan
[2] Pfizer Japan Inc, Tokyo, Japan
[3] Hamamatsu Inst Clin Pharmacol & Therapeut, Hamamatsu, Shizuoka, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 06期
关键词：
D O I：
10.1016/j.clpt.2004.02.002
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：587 / 588
页数：2
相关论文
共 50 条
  • [1] Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole
    Imamura, Chiyo K.
    Furihata, Kenichi
    Okamoto, Shinichiro
    Tanigawara, Yusuke
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (04): : 408 - 413
  • [2] Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype
    Zonios, Dimitrios
    Yamazaki, Hiroshi
    Murayama, Norie
    Natarajan, Ven
    Palmore, Tara
    Childs, Richard
    Skinner, Jeff
    Bennett, John E.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (12): : 1941 - 1948
  • [3] The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro
    Xu, Ren-ai
    Gu, Er-min
    Liu, Teng-hui
    Ou-yang, Qiu-geng
    Hu, Guo-xin
    Cai, Jian-ping
    [J]. INFECTION AND DRUG RESISTANCE, 2018, 11 : 2129 - 2135
  • [4] Cytochrome P450 2C19 genetic polymorphisms in Ugandans
    Miura, Jun
    Obua, Celestino
    Abbo, Catherine
    Kaneko, Sunao
    Tateishi, Tomonori
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (03) : 319 - 320
  • [5] Cytochrome P450 2C19 genetic polymorphisms in Ugandans
    Jun Miura
    Celestino Obua
    Catherine Abbo
    Sunao Kaneko
    Tomonori Tateishi
    [J]. European Journal of Clinical Pharmacology, 2009, 65 : 319 - 320
  • [6] Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19
    R Timm
    R Kaiser
    J Lötsch
    U Heider
    O Sezer
    K Weisz
    M Montemurro
    I Roots
    I Cascorbi
    [J]. The Pharmacogenomics Journal, 2005, 5 : 365 - 373
  • [7] Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
    Zeruesenay Desta
    Xiaojiong Zhao
    Jae-Gook Shin
    David A. Flockhart
    [J]. Clinical Pharmacokinetics, 2002, 41 : 913 - 958
  • [8] Human Cytochromes P450: Focus on Cytochrome P450 2C19
    Zvyaga, Tatyana
    Chang, Shu-Ying
    Chen, Cliff
    Yang, Zheng
    Vuppugalla, Ragini
    Hurley, Jeremy
    Thorndike, Denise
    Wagner, Andrew
    Chimalakonda, Anjaneya
    Rodrigues, A. David
    [J]. DRUG METABOLISM AND DISPOSITION, 2012, 40 (09) : 1698 - 1711
  • [9] GENETIC POLYMORPHISM OF CYTOCHROME P450 (2C19) IN PATIENTS WITH RENAL TRANSPLANT
    Ciftci, Hayriye Senturk
    Tefik, Tzevat
    Turkmen, Aydin
    Nane, Ismet
    Oguz, Fatma Savran
    Aydin, Filiz
    [J]. TISSUE ANTIGENS, 2014, 84 (01): : 58 - 59
  • [10] Effects of Cytochrome P450 (CYP) 2C19 Genetic Polymorphisms on Voriconazole Serum Levels: A Report of Two Cases
    Tas, Zahit
    Kara, Emre
    Deger, Ozan
    Ispirli, Mukaddes
    Metan, Gokhan
    Babaoglu, Melih O.
    Akova, Murat
    [J]. MEDITERRANEAN JOURNAL OF INFECTION MICROBES AND ANTIMICROBIALS, 2021, 10
12345